1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Corvus Aims To Master Adenosine Mechanisms For PD-1/L1 Failures

 
• By Emily Hayes

Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.

Emerging Company Profile Regular column feature image Version 2
Corvus Pharmaceuticals CEO Richard Miller

Corvus Pharmaceuticals Inc. hopes to catch the next wave of the immuno-oncology revolution by developing drugs that can treat patients who are resistant/refractory to PD-1/L1 inhibitors, by blocking the effects of the signaling molecule adenosine.

It's impossible to overestimate the impact that checkpoint inhibitors have had in cancer treatment. In some tumor types, however, response...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.